Travecta Therapeutics

Sweden
Slite, Gotland, Sweden, 139217

Company profile

Travecta Therapeutics company profile

ravecta is an emerging biotech company utilizing its novel Blood-Brain Barrier Transport Platform to develop a proprietary pipeline of molecules that treat disorders of the central nervous system. The Travecta Platform leverages their proprietary knowledge of the MFSD2a Transport for the targeted delivery of therapeutic agents to the brain. Their platform and know-how allow us to identify and categorize small molecules for enabling their transport across the blood-brain barrier (BBB). Additionally, Travecta partners with pharmaceutical companies to apply their platform and assist them in overcoming the challenges associated with delivering drugs across the BBB. Travecta’s process allows partners to rapidly confirm BBB transport through feasibility studies that generate in vitro and in vivo transport data of their molecule generated with Travecta’s proprietary models.

Business identity

Operating status
Closed
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0-$1M
Founded
2017-01-01, Year

Headquarters

Postal code
139217
Country code
SE
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
1
Total equity funding
$15M
Last funding
Series A / $15M / 2020-05-12
Last equity funding
Series A / $15M
Investors
1
Lead investors
1
Founders
2
Articles
7

Founders and investors

Founders

Laurent BenissanMahmood Ahmed

Lead investors

TKS1

Investors

TKS1